Literature DB >> 10448264

Prognostic significance of p53 codon 72 polymorphism in lung carcinomas.

Y C Wang1, H S Lee, S K Chen, Y Y Chang, C Y Chen.   

Abstract

Lung cancer is the leading cause of cancer death in Taiwan. Potential molecular markers associated with cancer susceptibility and prognosis are the genes involved in tumorigenesis. Therefore, we investigated the association of p53 codon 72 polymorphism with prognosis in 114 lung cancer patients. The estimated median survival times for patients with proline (Pro)/Pro, arginine (Arg)/Arg, and Arg/Pro genotypes were 25, 26 and 36 months, respectively. We also found that patients with the Pro/Pro genotype had a worse prognosis compared with those with Arg/Pro genotypes, especially for patients with squamous cell lung cancer (P = 0.013), male patients (P = 0.028) and those aged 60-69 years (P = 0.052). In patients with early stage lung cancer, patients with Pro/Pro and Arg/Arg genotypes had a tendency for a worse prognosis than those with the Arg/Pro genotype (P = 0.057). Our data suggest that p53 codon 72 polymorphism may be a potential prognostic factor in certain sub groups of lung cancer patients in Taiwan.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448264     DOI: 10.1016/s0959-8049(98)00369-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  26 in total

1.  Distributions of p53 codon 72 polymorphism in primary open angle glaucoma.

Authors:  H-J Lin; W-C Chen; F-J Tsai; S-W Tsai
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

2.  P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions.

Authors:  James Sul; Guo-Pei Yu; Qing-Yi Lu; Ming-Lan Lu; Veronica Wendy Setiawan; Ming-Rong Wang; Chun Hua Guo; Shun-Zhang Yu; Lina Mu; Lin Cai; Robert C Kurtz; Zuo-Feng Zhang
Journal:  Cancer Lett       Date:  2005-08-19       Impact factor: 8.679

3.  Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis.

Authors:  Jing Zhang; Wen-Lei Zhuo; Ying Zheng; Yun-Song Zhang
Journal:  Med Oncol       Date:  2009-06-05       Impact factor: 3.064

4.  p53 Pro72Arg polymorphism and prostate cancer in men of African descent.

Authors:  L Ricks-Santi; T Mason; V Apprey; C Ahaghotu; A McLauchlin; D Josey; G Bonney; G M Dunston
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

Review 5.  Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis.

Authors:  Yu Lu; Yanqiong Liu; Jie Zeng; Yu He; Qiliu Peng; Yan Deng; Jian Wang; Li Xie; Taijie Li; Xue Qin; Shan Li
Journal:  Tumour Biol       Date:  2014-02-01

6.  Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.

Authors:  Ankita Kumari; Charu Bahl; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Mol Biol Rep       Date:  2016-09-10       Impact factor: 2.316

7.  TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort.

Authors:  Helena S Thurow; Ricardo Haack; Fernando P Hartwig; Isabel O De Oliveira; Odir A Dellagostin; Denise P Gigante; Bernardo L Horta; Tiago Collares; Fabiana K Seixas
Journal:  J Biosci       Date:  2011-12       Impact factor: 1.826

8.  A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer.

Authors:  Sun Young Yi; Woon Jung Lee
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

9.  The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea.

Authors:  Nayoung Kim; Sung-Il Cho; Hye Seung Lee; Ji Hyun Park; Jee Hyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2009-01-29       Impact factor: 3.199

10.  Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India.

Authors:  Sanjay Katiyar; B K Thelma; N S Murthy; Suresh Hedau; Neeraj Jain; V Gopalkrishna; Syed Akhtar Husain; Bhudev C Das
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.